Literature DB >> 25705636

Multifocal hepatocellular carcinoma: intrahepatic metastasis or multicentric carcinogenesis?

Francesco Feo1, Rosa M Pascale1.   

Abstract

Multifocal Hepatocellular carcinoma (HCC) may be multiple HCCs of multicentric origin (MO) or intrahepatic metastases (IM) arising from a primary HCC. Numerous attempts to differentiate the two types of multifocal HCC have been made including the valuation of the clinicopathologic characteristics of MO and IM patients and the recurrence time, loss-of-heterozygosity analysis of specific DNA microsatellite loci to distinguish multiclonal MO from IM of monoclonal origin, and the research of diagnostic and progression markers through genomic and proteomic analyses. These approaches, however, have been unsatisfactory hitherto. Recently, a multi-omic analysis of HBV-related multifocal HCCs, including intergraded genomics and transcriptomics, was performed and the results, validated by a cohort of 174 HCC patients, were correlated with HCC clinicopathological data. The two multifocal HCC types were effectively discerned by multi-omics profiling that could predict HCC clonality and aggressiveness. Further, the dual-specificity protein kinase TTK was recognized as a prognostic marker for HCC. Multi-omics strategy potentially opens new perspectives for the diagnosis, prognosis and personalized treatment of multi-focal HCC. Further work aimed at extending this strategy to HCC with other etiology, simplifying the analysis, and reducing its costs is necessary for its routine clinical application.

Entities:  

Keywords:  HCC recurrence; genomics; multi-omics profiling; multifocal HCC; proteomics

Year:  2015        PMID: 25705636      PMCID: PMC4293477          DOI: 10.3978/j.issn.2305-5839.2014.12.08

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  20 in total

1.  Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution's experience with 398 consecutive patients.

Authors:  Zheng-Gui Du; Yong-Gang Wei; Ke-Fei Chen; Bo Li
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2014-04

Review 2.  Comparative analysis of the liver and plasma proteomes as a novel and powerful strategy for hepatocellular carcinoma biomarker discovery.

Authors:  Laura Beretta
Journal:  Cancer Lett       Date:  2009-02-15       Impact factor: 8.679

3.  Clinicopathologic characteristics and prognoses for multicentric occurrence and intrahepatic metastasis in synchronous multinodular hepatocellular carcinoma patients.

Authors:  Shi-Lai Li; Ming Su; Tao Peng; Kai-Yin Xiao; Li-Ming Shang; Bang-Hao Xu; Zhi-Xiong Su; Xin-Ping Ye; Ning Peng; Quan-Lin Qin; De-Feng Chen; Jie Chen; Le-Qun Li
Journal:  Asian Pac J Cancer Prev       Date:  2013

4.  Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis.

Authors:  Irene Oi-lin Ng; Xin-yuan Guan; Ronnie Tung-ping Poon; Sheung-Tat Fan; Joyce Man-Fong Lee
Journal:  J Pathol       Date:  2003-03       Impact factor: 7.996

5.  Enrichment map: a network-based method for gene-set enrichment visualization and interpretation.

Authors:  Daniele Merico; Ruth Isserlin; Oliver Stueker; Andrew Emili; Gary D Bader
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

Review 6.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

7.  Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas.

Authors:  Osakuni Morimoto; Hiroaki Nagano; Masato Sakon; Yoshiyuki Fujiwara; Terumasa Yamada; Hidewaki Nakagawa; Atsushi Miyamoto; Motoi Kondo; Isao Arai; Tameyoshi Yamamoto; Hideo Ota; Keizo Dono; Koji Umeshita; Shoji Nakamori; Yo Sasaki; Osamu Ishikawa; Shingi Imaoka; Morito Monden
Journal:  J Hepatol       Date:  2003-08       Impact factor: 25.083

Review 8.  Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.

Authors:  Maddalena Frau; Francesco Feo; Rosa M Pascale
Journal:  J Hepatol       Date:  2013-05-07       Impact factor: 25.083

Review 9.  Epidemiology of hepatocellular carcinoma: consider the population.

Authors:  Sahil Mittal; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2013-07       Impact factor: 3.062

10.  Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma.

Authors:  S Nomoto; T Kinoshita; K Kato; S Otani; H Kasuya; S Takeda; N Kanazumi; H Sugimoto; A Nakao
Journal:  Br J Cancer       Date:  2007-10-30       Impact factor: 7.640

View more
  26 in total

1.  Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy.

Authors:  David D Aufhauser; Eran Sadot; Douglas R Murken; Kevin Eddinger; Maarouf Hoteit; Peter L Abt; David S Goldberg; Ronald P DeMatteo; Matthew H Levine
Journal:  Ann Surg       Date:  2018-05       Impact factor: 12.969

2.  Rab31 promoted hepatocellular carcinoma (HCC) progression via inhibition of cell apoptosis induced by PI3K/AKT/Bcl-2/BAX pathway.

Authors:  Yanxia Sui; Xiaoqiang Zheng; Dongli Zhao
Journal:  Tumour Biol       Date:  2015-06-06

3.  Distinct Recurrence Risk Factors for Intrahepatic Metastasis and Multicenter Occurrence After Surgery in Patients with Hepatocellular Carcinoma.

Authors:  Shenghua Hao; Ping Fan; Shaofei Chen; Caixue Tu; Chidan Wan
Journal:  J Gastrointest Surg       Date:  2016-11-04       Impact factor: 3.452

Review 4.  Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma.

Authors:  Laura Amicone; Alessandra Marchetti
Journal:  Transl Gastroenterol Hepatol       Date:  2018-05-02

5.  Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma.

Authors:  L X Xu; M H He; Z H Dai; J Yu; J G Wang; X C Li; B B Jiang; Z F Ke; T H Su; Z W Peng; Y Guo; Z B Chen; S L Chen; S Peng; M Kuang
Journal:  Ann Oncol       Date:  2019-06-01       Impact factor: 32.976

6.  Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection.

Authors:  Samantha M Ruff; Luke D Rothermel; Laurence P Diggs; Michael M Wach; Reed I Ayabe; Sean P Martin; David Boulware; Daniel Anaya; Jeremy L Davis; John E Mullinax; Jonathan M Hernandez
Journal:  HPB (Oxford)       Date:  2019-11-13       Impact factor: 3.647

Review 7.  Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma.

Authors:  María de Guadalupe Chávez-López; Violeta Zúñiga-García; Julio Isael Pérez-Carreón; Arturo Avalos-Fuentes; Yesenia Escobar; Javier Camacho
Journal:  Biologics       Date:  2016-09-20

8.  MST4 negatively regulates the EMT, invasion and metastasis of HCC cells by inactivating PI3K/AKT/Snail1 axis.

Authors:  Mei-Juan Dian; Jing Li; Xiao-Ling Zhang; Zi-Jian Li; Ying Zhou; Wei Zhou; Qiu-Ling Zhong; Wen-Qian Pang; Xiao-Lin Lin; Tao Liu; Yi-An Liu; Yong-Long Li; Liu-Xin Han; Wen-Tao Zhao; Jun-Shuang Jia; Sheng-Jun Xiao; Dong Xiao; Jia-Wei Xia; Wei-Chao Hao
Journal:  J Cancer       Date:  2021-05-27       Impact factor: 4.207

9.  CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.

Authors:  Jiliang Feng; Ruidong Zhu; Chun Chang; Lu Yu; Fang Cao; Guohua Zhu; Feng Chen; Hui Xia; Fudong Lv; Shijie Zhang; Lin Sun
Journal:  PLoS One       Date:  2016-03-15       Impact factor: 3.240

10.  Hepatic resection provided long-term survival for patients with intermediate and advanced-stage resectable hepatocellular carcinoma.

Authors:  Wei Liu; Kun Wang; Quan Bao; Yi Sun; Bao-Cai Xing
Journal:  World J Surg Oncol       Date:  2016-03-02       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.